The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Open accessAbstract
IDH1 and IDH2 mutations occur frequently in gliomas and acute myeloid leukemia, leading to simultaneous loss and gain of activities in the production of α-ketoglutarate (α-KG) and 2-hydroxyglutarate (2-HG), respectively. Here we demonstrate that 2-HG is a competitive inhibitor of multiple α-KG-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases. 2-HG occupies the same space as α-KG does in the active site of histone demethylases. Ectopic expression of tumor-derived IDH1 and IDH2 mutants inhibits histone demethylation and 5mC hydroxylation. In glioma, IDH1 mutations are associated with increased histone methylation and decreased 5-hydroxylmethylcytosine (5hmC). Hence, tumor-derived IDH1 and IDH2 mutations reduce α-KG and accumulate an α-KG antagonist, 2-HG, leading to genome-wide histone and DNA methylation alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [5]
In the citing paper
“The observation that IDH1 and IDH2 mutations can partially phenocopy the loss of TET function may explain the mutual exclusivity of these mutations in cancer 95,97 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [97]
In the citing paper
“Mutant IDH protein is a competitive inhibitor of hydroxylases, including the TET family of 5mC hydroxylases120–122.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [122]
In the citing paper
“These observations support a model in which PU.1 guides TET2 to a specific subset of genomic regions to facilitate the oxidation of 5mC to 5hmC, a reaction that is inhibited by 2-hydroxyglutarate47 and enhanced by vitamin C13 (Figure 5d).”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [47]
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [81]
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [81]
In the citing paper
“Furthermore, TH17 cell differentiation could be initiated by exogenous addition of D-2-HG to naïve CD4+ T cells or by genetic silencing of TET1 and TET2, established targets of 2-HG143-145.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 2×
“HIF-1a is a transcription factor whose function is linked to metabolism, angiogenesis and tumorigenesis, and whose protein level is downregulated under normoxic conditions by PHD-mediated hydroxylation and subsequent hydroxylation-targeted ubiquitination (Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2…”
Self-citationEndostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Flagged first, then by citations
1 of the 55 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Han, 2007, Structural basis for histone demethylation by JHDM1, Frontier Science, 1, 52
Cited by
Sorted by citations
Items 701–800 of 1,006
Sulfur metabolism and its contribution to malignancy
Ward, N. P., & DeNicola, G. M. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.05.001 · Cited by 74
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase
Zheng, B., Yao, Y., Liu, Z., Deng, L., Anglin, J. L., Jiang, H., Prasad, B. V. V., & Song, Y. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400036z · Cited by 76
Becker‐Kettern, J., Paczia, N., Conrotte, J., Kay, D. P., Guignard, C., Jung, P. P., & Linster, C. L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.704494 · Cited by 76
Colorectal cancer: epigenetic alterations and their clinical implications
Puccini, A., Berger, M. D., Naseem, M., Tokunaga, R., Battaglin, F., Cao, S., Hanna, D. L., McSkane, M., Soni, S., Zhang, W., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.09.003 · Cited by 76
Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond
Teoh, S. T., & Lunt, S. Y. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1406 · Cited by 77
OH, the Places You’ll Go! Hydroxylation, Gene Expression, and Cancer
Ploumakis, A., & Coleman, M. L. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.026 · Cited by 77
Dąbrowski, M. J., & Wojtaś, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143478 · Cited by 73
Metabolic Mechanisms of Epigenetic Regulation
Meier, J. L. (2013) · ACS Chemical Biology · doi:10.1021/cb400689r · Cited by 75
Reduction of DNA hydroxymethylation in the mouse kidney insulted by ischemia reperfusion
Huang, N., Tan, L., Xue, Z., Cang, J., & Wang, H. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.061 · Cited by 74
Koivunen, P., & Laukka, T. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2721-8 · Cited by 76
Inhibition of a K9/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma
Voon, H. P. J., Udugama, M., Lin, W., Hii, L. L., Law, R. H. P., Steer, D. L., Das, P. P., Mann, J. R., & Wong, L. H. (2018) · Nature Communications · doi:10.1038/s41467-018-05607-5 · Cited by 79
Clinical impact of molecular biomarkers in gliomas
Siegal, T. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.10.004 · Cited by 76
Nakagawa, M., Nakatani, F., Matsunaga, H., Seki, T., Endo, M., Ogawara, Y., Machida, Y., Katsumoto, T., Yamagata, K., Hattori, A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0929-9 · Cited by 78
The Tricarboxylic Acid Cycle at the Crossroad Between Cancer and Immunity
Scagliola, A., Mainini, F., & Cardaci, S. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7974 · Cited by 75
Oxidative stress-mediated alterations in histone post-translational modifications
García‐Giménez, J. L., Garcés, C., Mateo, C. R., & Pallardó, F. V. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.02.027 · Cited by 75
Mitochondrial Citrate Transporter-dependent Metabolic Signature in the 22q11.2 Deletion Syndrome
Napoli, E., Tassone, F., Wong, S., Angkustsiri, K., Simon, T. J., Song, G., & Giulivi, C. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.672360 · Cited by 71
Isocitrate dehydrogenase mutations in leukemia
McKenney, A. S., & Levine, R. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67266 · Cited by 78
Chen, J.-Y., Lai, Y.-S., Tsai, H., Kuo, C.-C., Yen, B. L., Yeh, S., Sun, H. S., & Hung, W.-C. (2016) · Scientific Reports · doi:10.1038/srep32428 · Cited by 75
Mitochondrial dependency in progression of acute myeloid leukemia
Basak, N. P., & Banerjee, S. (2015) · Mitochondrion · doi:10.1016/j.mito.2015.01.006 · Cited by 75
Impact of Genetic Features on Treatment Decisions in AML
Döhner, H., & Gaidzik, V. I. (2011) · Hematology · doi:10.1182/asheducation-2011.1.36 · Cited by 72
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2
Ma, R., & Yun, C. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.08.068 · Cited by 73
The oncometabolite 2-hydroxyglutarate inhibits microglial activation via the AMPK/mTOR/NF-κB pathway
Han, C., Zheng, J., Sun, L., Yang, H., Cao, Z., Zhang, X., Zheng, L. T., & Zhen, X.-C. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0225-9 · Cited by 75
Self-citationXu, H., Sun, Y., You, B., Huang, C., Ye, D., & Chang, C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.014 · Cited by 72
Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development
Stanchina, M., Soong, D., Zheng-Lin, B., Watts, J. M., & Taylor, J. (2020) · Cancers · doi:10.3390/cancers12113225 · Cited by 72
Emerging Roles of SIRT5 in Metabolism, Cancer, and SARS-CoV-2 Infection
Fabbrizi, E., Fiorentino, F., Carafa, V., Altucci, L., Mai, A., & Rotili, D. (2023) · Cells · doi:10.3390/cells12060852 · Cited by 77
Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin
Griffin, G. K., Booth, C. A. G., Togami, K., Chung, S. S., Ssozi, D., Verga, J. A., Bouyssou, J., Lee, Y. S., Shanmugam, V., Hornick, J. L., et al. (2023) · Nature · doi:10.1038/s41586-023-06156-8 · Cited by 70
A Systems Approach to Predict Oncometabolites via Context-Specific Genome-Scale Metabolic Networks
Nam, H., Campodonico, M. A., Bordbar, A., Hyduke, D. R., Kim, S., Zielinski, D. C., & Palsson, B. Ø. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003837 · Cited by 71
Self-citationCAB39L elicited an anti-Warburg effect via a LKB1-AMPK-PGC1α axis to inhibit gastric tumorigenesis
Li, W., Wong, C. C., Zhang, X., Kang, W., Nakatsu, G., Zhao, Q., Chen, H., Go, M. Y. Y., Chiu, P. W. Y., Wang, X., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0402-1 · Cited by 74
Uo, T., Sprenger, C. C. T., & Plymate, S. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.580617 · Cited by 76
Wick, A., Bähr, O., Schüler, M., Rohrberg, K. S., Chawla, S. P., Jankú, F., Schiff, D., Heinemann, V., Narita, Y., Lenz, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4256 · Cited by 71
Recent Advances of m6A Demethylases Inhibitors and Their Biological Functions in Human Diseases
You, Y.-Z., Fu, Y.-D., Huang, M.-J., Shen, D., Zhao, B., Liu, H., Zheng, Y., & Huang, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105815 · Cited by 71
Metabolic plasticity and regulation of T cell exhaustion
Li, F., Liu, H., Zhang, D., Ma, Y., & Zhu, B. (2022) · Immunology · doi:10.1111/imm.13575 · Cited by 73
Epigenetic dysregulation in glioma
Kondo, Y., Katsushima, K., Ohka, F., Natsume, A., & Shinjo, K. (2014) · Cancer Science · doi:10.1111/cas.12379 · Cited by 73
Pediatric gliomas as neurodevelopmental disorders
Baker, S. J., Ellison, D. W., & Gutmann, D. H. (2015) · Glia · doi:10.1002/glia.22945 · Cited by 76
Acetoacetate Accelerates Muscle Regeneration and Ameliorates Muscular Dystrophy in Mice
Zou, X., Meng, J., Li, L., Han, W., Li, C., Zhong, R., Miao, X., Cai, J. C., Zhang, Y., & Zhu, D. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.676510 · Cited by 70
Self-citationCleven, A. H. G., Suijker, J., Agrogiannis, G., Bruijn, I. H. B., Frizzell, N., Hoekstra, A. S., Wijers‐Koster, P. M., Cleton-Jansen, A., & Bovée, J. V. M. G. (2017) · Clinical Sarcoma Research · doi:10.1186/s13569-017-0074-6 · Cited by 72
Metabolic signatures of human breast cancer
Mishra, P., & Ambs, S. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.992217 · Cited by 70
DNA methylation and hydroxymethylation in hematologic differentiation and transformation
Ko, M., An, J., & Rao, A. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.009 · Cited by 71
Chen, Q., Yin, D., Zhang, Y., Yu, L., Li, X., Zhou, Z., Zhou, S., Gao, D., Hu, J., Jin, C. S., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.142 · Cited by 71
Self-citationDifferentiation therapy of myeloid leukemia: four decades of development
Madan, V., & Koeffler, H. P. (2020) · Haematologica · doi:10.3324/haematol.2020.262121 · Cited by 72
Biology of IDH mutant cholangiocarcinoma
Wu, M., Shi, L., Merritt, J., Zhu, A. X., & Bardeesy, N. M. (2022) · Hepatology · doi:10.1002/hep.32424 · Cited by 71
Jin, Y., Elalaf, H., Watanabe, M., Tamaki, S., Hineno, S., Matsunaga, K., Woltjen, K., Kobayashi, Y., Nagata, S., Ikeya, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131998 · Cited by 70
de Cubas, A. A., Korpershoek, E., Inglada‐Pérez, L., Letouzé, É., Currás-Freixes, M., Fernández, A. F., Comino‐Méndez, I., Schiavi, F., Mančíková, V., Eisenhofer, G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2804 · Cited by 73
Toward Individualized Therapy in Acute Myeloid Leukemia
Kadia, T. M., Ravandi, F., Cortes, J. E., & Kantarjian, H. M. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0617 · Cited by 71
Kim, W. B., & Liau, L. M. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.04.009 · Cited by 71
Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2
Borodovsky, A., Seltzer, M. J., & Riggins, G. J. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834d816a · Cited by 71
Urban, D. J., Martinez, N. J., Davis, M. I., Brimacombe, K. R., Cheff, D. M., Lee, T. D., Henderson, M. J., Titus, S. A., Pragani, R., Rohde, J. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12630-x · Cited by 71
Self-citationDemarest, T. G., Varma, V. R., Estrada, D. J., Babbar, M., Basu, S., Mahajan, U. V., Moaddel, R., Croteau, D. L., Thambisetty, M., Mattson, M. P., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02152-8 · Cited by 74
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma
Spitzer, A., Gritsch, S., Nomura, M., Jucht, A., Fortin, J., Raviram, R., Weisman, H. R., Gonzalez Castro, L. N., Druck, N., Chanoch-Myers, R., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.03.008 · Cited by 69
Therapeutic Potential and Activity Modulation of the Protein Lysine Deacylase Sirtuin 5
Fiorentino, F., Castiello, C., Mai, A., & Rotili, D. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00687 · Cited by 70
IDH1: Linking Metabolism and Epigenetics
Raineri, S., & Mellor, J. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00493 · Cited by 70
The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
Nassereddine, S., Lap, C. J. G., Haroun, F., & Tabbara, I. A. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3161-0 · Cited by 69
Miller, J. J. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01238-3 · Cited by 70
Jiang, H., Li, A. M., & Ye, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004978 · Cited by 69
Wei, H., Suo, C., Gu, X., Shen, S., Lin, K., Zhu, C., Yan, K., Bian, Z., Chen, L., Zhang, T., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.011 · Cited by 72
Kreth, S., Thon, N., & Kreth, F. W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.008 · Cited by 68
Ten Eleven Translocation Enzymes and 5-Hydroxymethylation in Mammalian Development and Cancer
Kinney, S. R. M., & Pradhan, S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-9967-2_3 · Cited by 68
Khurshed, M., Molenaar, R. J., Lenting, K., Leenders, W. P. J., & Noorden, C. J. F. V. (2017) · Oncotarget · doi:10.18632/oncotarget.17106 · Cited by 72
Stuani, L., Riols, F., Millard, P., Sabatier, M., Batut, A., Saland, E., Viars, F., Tonini, L., Zaghdoudi, S., Linares, L. K., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113325 · Cited by 72
Isocitrate dehydrogenase variants in cancer — Cellular consequences and therapeutic opportunities
Liu, S., Cadoux-Hudson, T. A. D., & Schofield, C. J. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.06.012 · Cited by 70
Christians, A., Adel-Horowski, A., Banan, R., Lehmann, U., Bartels, S., Behling, F., Barrantes‐Freer, A., Stadelmann, C., Rohde, V., Stockhammer, F., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0817-0 · Cited by 67
Metabolite proofreading, a neglected aspect of intermediary metabolism
SCHAFTINGEN, E. V., Rim, R., Marbaix, A., Collard, F., Veiga‐da‐Cunha, M., & Linster, C. L. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9571-1 · Cited by 67
Molecular mechanisms and therapeutic targets in pediatric brain tumors
Liu, K.-W., Pajtler, K. W., Worst, B. C., Pfister, S. M., & Wechsler‐Reya, R. J. (2017) · Science Signaling · doi:10.1126/scisignal.aaf7593 · Cited by 67
Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation
Wang, E., Zhou, H., Nadorp, B., Cayanan, G., Chen, X., Yeaton, A. H., Nomikou, S., Witkowski, M. T., Narang, S., Kloetgen, A., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2020.12.005 · Cited by 66
Mitochondrial health, the epigenome and healthspan
Aon, M. A., Cortassa, S., Juhaszova, M., & Sollott, S. J. (2016) · Clinical Science · doi:10.1042/cs20160002 · Cited by 66
Duchmann, M., Micol, J., Duployez, N., Raffoux, E., Thomas, X., Marolleau, J., Braun, T., Adès, L., Chantepie, S., Lemasle, É., et al. (2021) · Blood · doi:10.1182/blood.2020010165 · Cited by 66
Regulation of antitumor immunity by inflammation-induced epigenetic alterations
Karin, M., & Shalapour, S. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00756-y · Cited by 68
Role of Branched-chain Amino Acid Metabolism in Tumor Development and Progression
Jung, M. K., Okekunle, A. P., Lee, J. E., Sung, M. K., & Lim, Y. J. (2021) · Journal of Cancer Prevention · doi:10.15430/jcp.2021.26.4.237 · Cited by 66
Impact of epigenetic reprogramming on antitumor immune responses in glioma
McClellan, B. L., Haase, S., Núñez, F. J., Alghamri, M. S., Dabaja, A. A., Lowenstein, P. R., & Castro, M. G. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163450 · Cited by 68
Chen, Z., He, Q., Lu, T., Wu, J., Shi, G., He, L., Zong, H., Liu, B., & Zhu, P. (2023) · Nature Communications · doi:10.1038/s41467-023-36651-5 · Cited by 67
Compendium of aberrant DNA methylation and histone modifications in cancer
Hattori, N., & Ushijima, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.140 · Cited by 72
Mohrenz, I. V., Antonietti, P., Pusch, S., Capper, D., Balß, J., Voigt, S., Weißert, S., Mukrowsky, A., Frank, J., Senft, C., et al. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0877-8 · Cited by 66
Andreoli, F., Barbosa, A. J. M., Parenti, M. D., & Río, A. D. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804581918 · Cited by 68
Zhang, M., Gao, C., Guo, X., Guo, S., Kang, Z., Xiao, D., Yan, J., Tao, F., Zhang, W., Dong, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04513-0 · Cited by 66
Self-citationOntogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function
Ivanov, M., Kals, M., Kacevska, M., Barragán, I., Kasuga, K., Rane, A., Metspalu, A., Milani, L. A., & Ingelman‐Sundberg, M. (2013) · Genome biology · doi:10.1186/gb-2013-14-8-r83 · Cited by 65
Xiong, J., Tan, W., Wen, J., Pan, J., Wang, Y., Zhang, J., & Geng, D. (2015) · European Radiology · doi:10.1007/s00330-015-4025-4 · Cited by 65
Self-citationZhang, L., Liu, Y., Wang, M., Wu, Z., Li, N., Zhang, J., & Yang, C. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx056 · Cited by 65
Self-citationThe role of epigenetics in the development of obesity
Obri, A., Serra, D., Herrero, L., & Mera, P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113973 · Cited by 71
Oxygen regulation of TET enzymes
Matulevičiūtė, R., Cunha, P. P., Johnson, R. S., & Foskolou, I. P. (2021) · FEBS Journal · doi:10.1111/febs.15695 · Cited by 69
Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma
Duraj, T., Kalamian, M., Zuccoli, G., Maroon, J. C., D’Agostino, D. P., Scheck, A. C., Poff, A. M., Winter, S. F., Hu, J. L., Klement, R. J., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03775-4 · Cited by 65
Peptide vaccines for the treatment of glioblastoma
Swartz, A. M., Batich, K. A., Fecci, P. E., & Sampson, J. H. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1676-y · Cited by 64
Kunimoto, H., Fukuchi, Y., Sakurai, M., Sadahira, K., Ikeda, Y., Okamoto, S., & Nakajima, H. (2012) · Scientific Reports · doi:10.1038/srep00273 · Cited by 71
Natsumeda, M., Igarashi, H., Nomura, T., Ogura, R., Tsukamoto, Y., Kobayashi, T., Aoki, H., Okamoto, K., Kakita, A., Takahashi, H., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0158-y · Cited by 64
TET1 inhibits gastric cancer growth and metastasis by PTEN demethylation and re-expression
Pei, Y.-F., Tao, R. N., Li, J., Su, L., Yu, B., Wu, X., Yan, M., Gu, Q., Zhu, Z., & Liu, B. (2016) · Oncotarget · doi:10.18632/oncotarget.8900 · Cited by 65
Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma
Mariño‐Enríquez, A., & Bovée, J. V. M. G. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.04.009 · Cited by 69
Kalsoom, A., Maqsood, M., Ghazanfar, M. A., Aadil, F., & Rho, S. (2018) · The Journal of Supercomputing · doi:10.1007/s11227-018-2326-5 · Cited by 65
Ogura, R., Tsukamoto, Y., Natsumeda, M., Isogawa, M., Aoki, H., Kobayashi, T., Yoshida, S., Okamoto, K., Takahashi, H., Fujii, Y., et al. (2015) · Neuropathology · doi:10.1111/neup.12196 · Cited by 64
Linking Cancer Metabolism to DNA Repair and Accelerated Senescence
Efimova, E. V., Takahashi, S., Shamsi, N. A., Wu, D., Labay, E., Ulanovskaya, O. A., Weichselbaum, R. R., Kozmin, S. A., & Kron, S. J. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0263 · Cited by 65
Mitochondrial Retrograde Signalling and Metabolic Alterations in the Tumour Microenvironment
Yang, D., & Kim, J. (2019) · Cells · doi:10.3390/cells8030275 · Cited by 67
Li, Y., Gruber, J. J., Litzenburger, U. M., Zhou, Y., Miao, Y. R., LaGory, E. L., Li, A. M., Hu, Z., Yip, M., Hart, L. S., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2303-9 · Cited by 65
Myc-mediated SDHA acetylation triggers epigenetic regulation of gene expression and tumorigenesis
Li, S., Huang, D., Shen, S., Cai, Y., Xing, S., Wu, G., Jiang, Z., Hao, Y., Yuan, M., Wang, N., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0179-8 · Cited by 72
Cancer cell metabolism: Rewiring the mitochondrial hub
Oliveira, G. L., Coelho, A. R., Marques, R., & Oliveira, P. J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166016 · Cited by 65
Rethinking pheochromocytomas and paragangliomas from a genomic perspective
Castro‐Vega, L. J., Lussey‐Lepoutre, C., Gimenez‐Roqueplo, A., & Favier, J. (2015) · Oncogene · doi:10.1038/onc.2015.172 · Cited by 76
Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism
Pollard, P. J., Yang, M. H., Su, H., Soga, T., & Kranc, K. R. (2014) · Hypoxia · doi:10.2147/hp.s47968 · Cited by 66
Chou, A. P., Chowdhury, R., Li, S., Chen, W., Kim, A. J., Piccioni, D. E., Selfridge, J. M., Mody, R. R., Chang, S., Lalezari, S., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs357 · Cited by 67
Metabolic synthetic lethality in cancer therapy
Zecchini, V. R., & Frezza, C. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.12.003 · Cited by 63
Cellular Compartmentation and the Redox/Nonredox Functions of NAD +
Kulkarni, C. A., & Brookes, P. S. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7722 · Cited by 68
Solid tumours hijack the histone variant network
Ghiraldini, F. G., Filipescu, D., & Bernstein, E. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-020-00330-0 · Cited by 68
Batsios, G., Viswanath, P., Subramani, E., Najac, C., Gillespie, A. M., Santos, R. D., Molloy, A. R., Pieper, R. O., & Ronen, S. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-47021-x · Cited by 63
Konstandin, N. P., Bultmann, S., Szwagierczak, A., Dufour, A., Ksienzyk, B., Schneider, F., Herold, T., Mulaw, M. A., Kakadia, P. M., Schneider, S.-R., et al. (2011) · Leukemia · doi:10.1038/leu.2011.134 · Cited by 67
Metadata
- Authors
- Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., Liu, L.-X., Jiang, W.-Q., Liu, J., Zhang, J.-Y., Wang, B., Frye, S., Zhang, Y., Xu, Y.-H., Lei, Q.-Y., Guan, K.-L., Zhao, S.-M., & Xiong, Y.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- University of North Carolina at Chapel Hill (US)
- Chinese Academy of Sciences (CN)
- Corresponding author
- Guan, Kun-Liang
- Xiong, Yue
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 19
- Issue
- 1
- Pages
- 17-30
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3229304
- OpenAlex
- W2131860315
- Cited by
- 2,875
- References
- 55
- Citations by year
- 2026: 165 · 2025: 168 · 2024: 192 · 2023: 182 · 2022: 183 · 2021: 270 · 2020: 214 · 2019: 191 · 2018: 195 · 2017: 183 · 2016: 196 · 2015: 180 · 2014: 183 · 2013: 157 · 2012: 137
- FWCI
- 90.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 928 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Natural Science Foundation of China (11079016, 30600112, 30871255, 30971485/C0706)
- Ministry of Education of the People's Republic of China
- National Key Research and Development Program of China (2011CB910600, 2011CB965300)
- Project 985
- Major State Basic Research Development Program of China (2009CB918401, 2009CB918600)
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- 2-hydroxyglutarate, oncometabolites, alpha-ketoglutarate-dependent dioxygenase, IDH1 mutation, IDH2 mutation, histone demethylase, 5-hydroxymethylcytosine, competitive inhibition, glioma, acute myeloid leukemia, DNA methylation, histone methylation, active site
- MeSH terms
- Animals, Binding, Competitive, Cytosine, DNA-Binding Proteins, Glioma, Glutarates, Histones, Humans, Mixed Function Oxygenases, Isocitrate Dehydrogenase, Ketoglutaric Acids, Models, Molecular, Oxalates, Oxidoreductases, N-Demethylating, Procollagen-Proline Dioxygenase, Proto-Oncogene Proteins, Gene Expression, Caenorhabditis elegans, Homeodomain Proteins, Amino Acid Substitution, Catalytic Domain, Caenorhabditis elegans Proteins, Endostatins, 5-Methylcytosine, F-Box Proteins, Cell Line, Tumor, Dioxygenases, Hypoxia-Inducible Factor 1, alpha Subunit, Biocatalysis, Histone Demethylases, Jumonji Domain-Containing Histone Demethylases, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
